Transpek Industries - Rs.93.00

Transpek Industries Ltd. (TIL) was actually set up in 1965 for manufacturing Transparent Acrylic Sheets and hence was named ‘Transpek’. Since then, the company has grown into a leading manufacturer and exporter of a range of chemicals servicing the requirements of textiles, pharmaceuticals, agrochemicals, polymers etc. In fact, today TIL is Asia’s largest manufacturer of Thionyl Chloride and Acid Chloride. Thionyl Chloride is an intermediate for crop protection chemicals in the agrochemicals industry. Managed by the Shroff family of Excel Industries fame, TIL used to be the largest and only manufacturer of sodium hydro sulfite, safolite, safoline, zinc oxide and zinc dust. But these businesses have been transferred to Transpek Silox Industry Ltd., a joint venture company.

With it’s expertise in sulphur and chlorine chemistry and ability to undertake projects involving sulphonation, acid chloride reaction, friedel-craft, esterification and high pressure reaction, TIL also does Custom Synthesis and Toll Manufacturing. Notably, its R&D activity is so strong that the manufacturing technologies for all its existing products are developed in-house. In fact, last fiscal it adopted improved technology for the manufacture of Thionyl Chloride and with de-bottlenecking enhanced its installed capacity from 16500 TPA to 19500 TPA. It is further planning to expand the capacity to 24000 TPA. Moreover, it has also commissioned the continuous Acid Chloride plant, which will lead to consistency in production and quality, better efficiency and lower man-power requirement. It is putting special thrust on exports and is in the process of tying up business with several reputed overseas companies. Also in order to hedge itself from the seasonality in business, the company is focusing on other market segments such as intermediates for pharmaceuticals, dyes and polymers.

Fundamentally, the company is doing extremely well. For the six months ending 30th Sept.’06, while sales increased by nearly 40% to Rs.47.50 cr. net profit zoomed 120% to Rs.4.30 cr. importantly, its OPM improved substantially to 21.50% against 16% last year. Assuming the same growth record, it is estimated to end FY07 with sales of Rs.100 cr. and net profit Rs.9 cr. This will lead to an EPS of Rs.18 on its current equity of Rs.5.07 and it may declare 35% dividend for FY07. Having a book value of Rs.70 and with a dividend yield of nearly 4%, this scrip is trading fairly cheap at P/E multiple of 5. Investors are recommended to buy it at declines with a price target of Rs.150 i.e. 50% return in 12-15 months.

IG Petrochemicals Ltd - Rs.72.00

Incorporated in 1988, IG Petrochemicals Ltd. (IGPL) is the world’s third largest producer of Pthalic Anhydride (PAN), mainly used in the manufacture of plasticizers for production of PVC products, shoe soles etc., Alkyd Resins used for manufacturing paints and as an intermediate in the production of dyes and pigments and for the in production of unsaturated Polyester Resins. IGPL is a recognized EOU with exports accounting for 75% of sales. It is an ISO accredited 9001:2000 company for Quality Management Systems from BVQI. A few years back, the company was in a very bad shape and registered as a sick company with BIFR. But by aggressive debt restructuring and better market conditions, it made a smart turnaround and is now on a strong footing. It has also been de-registered from BIFR in June’06 as its net worth has positive.

IGPL’s plant is located at MIDC-Taloja in Maharashtra, 50 kms away from JNPT in Nhavasheva and has an installed capacity of 1,20,000 MTPA. It uses the Orthoxylene Oxidation method which produces high-pressure steam that makes the plant self-sufficient in power and steam requirements and is therefore, one of the most cost-effective plants for manufacturing PAN in the world. Earlier, the company had to import its main raw material i.e. Orthoxylene at higher prices but now sources 70% indigenously from Reliance Industries at much lower cost. Also the price of PAN has risen substantially due to strong demand from the user industries. Importantly, the company is now working at 100% capacity utilization compare to less than 75% in FY06 and is planning to expand its production capacity to meet the rising demand. With higher capacity utilization coupled with better price realization, the company is witnessing one if its best times and is expected to end FY07 on a buoyant note.

Last fiscal, the company undertook major financial restructuring by settling the debts and liabilities of all banks and financial institutions. This was made possible by an investment of Rs.125 cr. by Spinnaker, a global fund, in the form of convertible debentures. Recently, IGPL came out with stunning numbers for the Dec.’06 quarter. Sales increased by 50% to Rs.150 cr. whereas it registered a net profit of Rs.10.90 cr. against net loss of Rs.15.60 cr. last year. Notably, it recorded the highest OPM of around 14% due to high realization, low raw material cost and increased capacity utilization. Besides, the recent fall in crude oil prices also augurs well for the company. For FY07, it is estimated to clock a turnover of Rs.600 cr. with PAT of Rs.33.50 cr. This translates into an EPS of Rs.13 on its current equity of Rs.26.30 cr. and EPS Of Rs.11 on its diluted equity of Rs.30.80 cr. Investors are advised to accumulate this scrip at sharp declines only as it has the potential to hit Rs.100 (50% appreciation) in 15-18 months.

STOCK WATCH

Lot of positive developments are taking place in Micro Technologies Ltd. (Code:532494) (Rs.267.50). The company has appointed Madison Communications, one of the top ad agencies for its publicity campaign. Recently, it also launched a unique Global e-Security product called Micro Internet Access Security System – BANK for banking industry to secure online-based accounts. This month, its Micro Vehicle Navigator System won approval from the Municipal Corporation UAE, which is a good breakthrough for the company in the global market. For the first half, its topline grew by 80% to Rs.48 cr. and PAT zoomed by 135% to Rs.13.90 cr. With its focus on Security, E-commerce, Telecommunication, Wireless Technology and GIS, its future is very promising and the company has potential to grow multifold. For FY07, it can register revenue of about Rs.100 cr. with profit of Rs.25 cr. i.e. EPS of Rs.24 on its equity of Rs.10.50 cr. For FY08, it can easily report Rs.30 EPS. Hence, the scrip may touch Rs.420 considering an average P/E multiple of 14 against its FY08 earnings.

Easun Reyrolle Ltd. (Code:532751) (Rs.629.45) is a strong and independent solution provider in power system protection, control, automation, metering and switching. Of late, it has ventured into construction of projects on turnkey basis wherein it will concentrate on substation projects and power system automation project. For the nine months ending 30th Sept.’06, its top-line as well as bottom-line grew by 25% to Rs.59 cr. and Rs.7.25 cr. respectively. For future growth, it is setting up a 45,000 sq ft world class manufacturing facility at Hosur for medium voltage switchgear at an investment of Rs.12 cr. and recently, its in-house R&D won recognition from Govt. of India (DSIR). For FY07, it is estimated to report a top-line of Rs.135 cr. and bottom-line of Rs.16 cr. This works out to an EPS of Rs.48 on its tiny equity of Rs.3.33 cr. For FY08, it may report EPS more than Rs.60. At a reasonable discounting by 14 against its FY08 earning, the scrip should trade around Rs.850. Given its huge reserve of Rs.35 cr. it is a strong bonus candidate as well. A strong buy.

Few broking firms have turned bullish on Jupiter Bioscience Ltd. (Code:524826) (Rs.136.40). As P/E ratio reports, the company has developed eight generic peptides which are ready for launch. Besides, Sven Genetech and its US subsidiary have formed another wholly-owned subsidiary in Japan to supply peptide and chiral intermediaries to the top four Japanese pharma companies. Moreover, it is setting up a 5500 sq. ft. manufacturing facility in Maryland, USA, to cater the US, Canadian and European markets. It is also looking to acquire few companies globally. To fund the company’s growth plans, the promoters are infusing Rs.40 cr. by subscribing to 27.5 lakh share warrants to be converted into equity shares at Rs.146 per share. Further Rs.95 cr. will be raised by debt and FCCB issue. For full year FY07, it is expected to clock a turnover of Rs.90 cr. with net profit of Rs.21 cr., which works out to an EPS of Rs.24 on its current equity of Rs.8.86 cr. However on its diluted equity of Rs.11.61 cr., EPS comes to around Rs.18. The company is at an inflexion point and its real growth will be witnessed in FY08 and FY09. A good long term bet.

Surya Pharma (Code:532516) (Rs.88) is among the top five Indian players in betalactum and cephalosporin range of anti-infectives and is gradually moving up the product value chain from being a manufacturer of betalactum antibiotics (a low-margin product) to a maker of third-and fourth-generation cephalosporin’s (a high-margin product). It has also diversified into the lucrative lifestyle segments like anti-histamines and cardio vascular drugs. Of late, it has made an impressive foray into contract research and manufacturing (CRAMS) space. Apart from carrying out massive capacity expansions at its existing facilities in Baddi and Banur, it is setting up a new US-FDA compliant facility in Jammu at an investment of Rs.90 cr. For FY07, it is estimated to clock a turnover of Rs.275 cr. and net profit of Rs.27 cr. which leads to an EPS of Rs.15 on its fully-diluted equity of around Rs.18 cr. Scrip can appreciate 50% in 9-12 months. Accumulate at declines.